Miriam Galbusera

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8346649/publications.pdf

Version: 2024-02-01

59 papers	5,927 citations	159585 30 h-index	161849 54 g-index
60 all docs	60 docs citations	60 times ranked	4289 citing authors

#	Article	IF	Citations
1	von Willebrand Factorâ€“Cleaving Protease in Thrombotic Thrombocytopenic Purpura and the Hemolyticâ€“Uremic Syndrome. New England Journal of Medicine, 1998, 339, 1578-1584.	27.0	1,717
2	Platelet Dysfunction in Renal Failure. Seminars in Thrombosis and Hemostasis, 2004, 30, 579-589.	2.7	393
3	Dynamics of complement activation in aHUS and how to monitor eculizumab therapy. Blood, 2014, 124, 1715-1726.	1.4	288
4	ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases. Blood, 2005, 106, 1262-1267.	1.4	275
5	Alternative Pathway Activation of Complement by Shiga Toxin Promotes Exuberant C3a Formation That Triggers Microvascular Thrombosis. Journal of Immunology, 2011, 187, 172-180.	0.8	220
6	von Willebrand factor cleaving protease (ADAMTS13) is deficient in recurrent and familial thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Blood, 2002, 100, 778-785.	1.4	200
7	Heterogeneity of plasma von Willebrand factor multimers resulting from proteolysis of the constituent subunit.. Journal of Clinical Investigation, 1991, 88, 774-782.	8.2	174
8	In Response to Protein Load Podocytes Reorganize Cytoskeleton and Modulate Endothelin-1 Gene. American Journal of Pathology, 2005, 166, 1309-1320.	3.8	151
9	Complement Factor H Mutation in Familial Thrombotic Thrombocytopenic Purpura with ADAMTS13 Deficiency and Renal Involvement. Journal of the American Society of Nephrology: JASN, 2005, 16, 1177-1183.	6.1	129
10	Treatment of Bleeding in Dialysis Patients. Seminars in Dialysis, 2009, 22, 279-286.	1.3	129
11	Fluid Shear Stress Modulates von Willebrand Factor Release From Human Vascular Endothelium. Blood, 1997, 90, 1558-1564.	1.4	123
12	Measurement of von Willebrand factor cleaving protease (ADAMTS-13): results of an international collaborative study involving 11 methods testing the same set of coded plasmas. Journal of Thrombosis and Haemostasis, 2004, 2, 1601-1609.	3.8	96
13	Reversible Activation Defect of the Platelet Glycoprotein IIb-IIIa Complex in Patients With Uremia. American Journal of Kidney Diseases, 1993, 22, 668-676.	1.9	92
14	Verotoxin-1â€“induced up-regulation of adhesive molecules renders microvascular endothelial cells thrombogenic at high shear stress. Blood, 2001, 98, 1828-1835.	1.4	92
15	Rituximab as pre-emptive treatment in patients with thrombotic thrombocytopenic purpura and evidence of anti-ADAMTS13 autoantibodies. Thrombosis and Haemostasis, 2009, 101, 233-238.	3.4	85
16	Complement activation: the missing link between ADAMTS-13 deficiency and microvascular thrombosis of thrombotic microangiopathies. Thrombosis and Haemostasis, 2005, 93, 443-452.	3.4	81
17	Thrombotic Thrombocytopenic Purpura: Evidence That Infusion Rather Than Removal of Plasma Induces Remission of the Disease. American Journal of Kidney Diseases, 1993, 21, 314-318.	1.9	73
18	In-vitro and in-vivo consequences of mutations in the von Willebrand factor cleaving protease ADAMTS13 in thrombotic thrombocytopenic purpura. Thrombosis and Haemostasis, 2006, 96, 454-464.	3.4	72

#	Article	IF	Citations
19	An ExÂVivo Test of Complement Activation on Endothelium for Individualized Eculizumab Therapy in Hemolytic Uremic Syndrome. American Journal of Kidney Diseases, 2019, 74, 56-72.	1.9	71
20	Membranous Nephropathy Associated With IgG4-Related Disease. American Journal of Kidney Diseases, 2011, 58, 272-275.	1.9	64
21	Involvement of renal tubular tollâ€like receptor 9 in the development of tubulointerstitial injury in systemic lupus. Arthritis and Rheumatism, 2007, 56, 1569-1578.	6.7	61
22	Blunted excretory response to atrial natriuretic peptide in experimental nephrosis. Kidney International, 1989, 36, 57-64.	5.2	57
23	Rituximab prevents recurrence of thrombotic thrombocytopenic purpura: a case report. Blood, 2005, 106, 925-928.	1.4	57
24	Interaction between Multimeric von Willebrand Factor and Complement: A Fresh Look to the Pathophysiology of Microvascular Thrombosis. Journal of Immunology, 2017, 199, 1021-1040.	0.8	56
25	Thrombotic Thrombocytopenic Purpura-Then and Now. Seminars in Thrombosis and Hemostasis, 2006, 32, 081-089.	2.7	52
26	Two Patients With History of STEC-HUS, Posttransplant Recurrence and Complement Gene Mutations. American Journal of Transplantation, 2013, 13, 2201-2206.	4.7	51
27	Bilateral nephrectomy stopped disease progression in plasma-resistant hemolytic uremic syndrome with neurological signs and coma. Kidney International, 1996, 49, 282-286.	5.2	47
28	SARS-CoV-2 Spike Protein 1 Activates Microvascular Endothelial Cells and Complement System Leading to Platelet Aggregation. Frontiers in Immunology, 2022, 13, 827146.	4.8	45
29	Increased Fragmentation of von Willebrand Factor, Due to Abnormal Cleavage of the Subunit, Parallels Disease Activity in Recurrent Hemolytic Uremic Syndrome and Thrombotic Thrombocytopenic Purpura and Discloses Predisposition in Families. Blood, 1999, 94, 610-620.	1.4	44
30	C5a and C5aR1 are key drivers of microvascular platelet aggregation in clinical entities spanning from aHUS to COVID-19. Blood Advances, 2022, 6, 866-881.	5.2	31
31	Inherited thrombotic thrombocytopenic purpura. Haematologica, 2009, 94, 166-170.	3.5	29
32	Catecholamine receptor binding in rat kidney: Effect of aging. Kidney International, 1988, 33, 1073-1077.	5.2	26
33	ADAMTS13 Predicts Renal and Cardiovascular Events in Type 2 Diabetic Patients and Response to Therapy. Diabetes, 2013, 62, 3599-3609.	0.6	25
34	Treatment of Congenital Thrombotic Thrombocytopenic Purpura With Eculizumab. American Journal of Kidney Diseases, 2015, 66, 1067-1070.	1.9	25
35	Eculizumab in patients with severe coronavirus disease 2019 (COVID-19) requiring continuous positive airway pressure ventilator support: Retrospective cohort study. PLoS ONE, 2021, 16, e0261113.	2.5	25
36	Deficiency of ADAMTS13 and thrombotic thrombocytopenic purpura. Blood, 2002, 100, 3839-3842.	1.4	24

#	Article	IF	Citations
37	Mitochondrial-dependent Autoimmunity in Membranous Nephropathy of IgG4-related Disease. EBioMedicine, 2015, 2, 456-466.	6.1	24
38	Unrecognized Pattern of von Willebrand Factor Abnormalities in Hemolytic Uremic Syndrome and Thrombotic Thrombocytopenic Purpura. Journal of the American Society of Nephrology: JASN, 1999, 10, 1234-1241.	6.1	23
39	Î±1-antitrypsin therapy in a case of thrombotic thrombocytopenic purpura. Lancet, The, 1995, 345, 224-225.	13.7	22
40	Liver transplantation for aHUS: still needed in the eculizumab era?. Pediatric Nephrology, 2016, 31, 759-768.	1.7	22
41	Defective Platelet Aggregation in Response to Platelet-Activating Factor in Uremia Associated With Low Platelet Thromboxane A2 Generation. American Journal of Kidney Diseases, 1992, 19, 318-325.	1.9	21
42	In-vitro and in-vivo consequences of mutations in the von Willebrand factor cleaving protease ADAMTS13 in thrombotic thrombocytopenic purpura. Thrombosis and Haemostasis, 2006, 96, 454-64.	3.4	20
43	Functional implications of decreased renal cortical atrial natriuretic peptide binding in experimental diabetes.. Circulation Research, 1990, 66, 1453-1460.	4.5	15
44	A novel interpretation of the role of von Willebrand factor in thrombotic microangiopathies based on platelet adhesion studies at high shear rate flow. American Journal of Kidney Diseases, 2000, 36, 695-702.	1.9	14
45	Activation of porcine endothelium in response to xenogeneic serum causes thrombosis independently of platelet activation. Xenotransplantation, 2005, 12, 110-120.	2.8	14
46	A Novel Antibody against Human Factor B that Blocks Formation of the C3bB Proconvertase and Inhibits Complement Activation in Disease Models. Journal of Immunology, 2014, 193, 5567-5575.	0.8	14
47	Adenoviral-mediated gene transfer restores plasma ADAMTS13 antigen and activity in ADAMTS13 knockout mice. Gene Therapy, 2009, 16, 1373-1379.	4.5	13
48	ADAMTS13 Secretion and Residual Activity among Patients with Congenital Thrombotic Thrombocytopenic Purpura with and without Renal Impairment. Clinical Journal of the American Society of Nephrology: CJASN, 2015, 10, 2002-2012.	4.5	12
49	Molecular Studies and an ex vivo Complement Assay on Endothelium Highlight the Genetic Complexity of Atypical Hemolytic Uremic Syndrome: The Case of a Pedigree With a Null CD46 Variant. Frontiers in Medicine, 2020, 7, 579418.	2.6	8
50	Fluid Shear Stress Modulates von Willebrand Factor Release From Human Vascular Endothelium. Blood, 1997, 90, 1558-1564.	1.4	8
51	Diverse Functional Implications of ADAMTS13 Gene Mutations in Patients with TTP and Congenital Deficiency.. Blood, 2004, 104, 513-513.	1.4	5
52	Case Report: Effects of Anti-SARS-CoV-2 Convalescent Antibodies Obtained With Double Filtration Plasmapheresis. Frontiers in Immunology, 2021, 12, 711915.	4.8	2
53	Bleeding and Hemostasis in Acute Renal Failure. , 2019, , 630-635.e2.		1
54	SARS-CoV-2 Spike Protein 1 Activates Microvascular Endothelial Cells and Complement System Leading to Thrombus Formation. SSRN Electronic Journal, 0, , .	0.4	1

#	Article	IF	Citations
55	Increased Fragmentation of von Willebrand Factor, Due to Abnormal Cleavage of the Subunit, Parallels Disease Activity in Recurrent Hemolytic Uremic Syndrome and Thrombotic Thrombocytopenic Purpura and Discloses Predisposition in Families. Blood, 1999, 94, 610-620.	1.4	1
56	Prevention and Therapeutic Management of Bleeding in Dialysis Patients. , 2008, , 445-456.		0
57	Prevention and Therapeutic Management of Bleeding in Dialysis Patients. , 2017, , 334-345.e1.		0
58	Bleeding and Hemostasis in Acute Renal Failure. , 2009, , 385-390.		0
59	Hemolytic Uremic Syndrome/Thrombotic Thrombocytopenic Purpura. , 2010, , 349-364.		0